Anterios, which is developing a topical formulation of botulinum toxin, postponed its IPO on Friday.
The New York, NY-based company had planned to raise $51 million by offering 3.9 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Anterios would have commanded a fully diluted market value of $182 million.
Close peer and February 2014 IPO Revance Therapeutics (RVNC; +70%) is up over 30% this week and over 60% year-to-date, climbing above its first-day closing price of $26.85 for the first time since August.
Founded in 2006, Anterios had planned to list on the NASDAQ under the symbol ANTE. Stifel and RBC Capital Markets were set to be the joint bookrunners on the deal. It is the third biotech to postpone its offering this week, after Gelesis (GLSS) and MultiVir (MVIR).
